alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2021290EN.01001801.xml

| 20.7.2021 | EN | Official Journal of the European Union | C 290/18 |
| --- | --- | --- | --- |

20.7.2021

EN

Official Journal of the European Union

C 290/18

---

Prior notification of a concentration

(Case M.10388 — Gamut/BCI/PS Parent)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 290/10)

1.

This notification concerns the following undertakings:

| — | Gamut Capital Management L.P. (United States) |
| --- | --- |

—

Gamut Capital Management L.P. (United States)

| — | British Columbia Investment Management Corporation (Canada) |
| --- | --- |

—

British Columbia Investment Management Corporation (Canada)

| — | PS Parent, LLC (United States) |
| --- | --- |

—

PS Parent, LLC (United States)

Gamut Capital Management L.P. and British Columbia Investment Management Corporation acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of PS Parent, LLC.

The concentration is accomplished by way of purchase of shares.

2.

| — | for Gamut Capital Management L.P.: private equity firm offering investment advisory services. |
| --- | --- |

—

for Gamut Capital Management L.P.: private equity firm offering investment advisory services.

| — | for British Columbia Investment Management Corporation: an agent of the Government of British Columbia investing on behalf of public sector clients across a range of asset classes. |
| --- | --- |

—

for British Columbia Investment Management Corporation: an agent of the Government of British Columbia investing on behalf of public sector clients across a range of asset classes.

| — | for PS Parent, LLC: transportation of freight on flatbed trailers, multi-modal freight brokerage, logistics services and warehousing services, outside of the European Economic Area. |
| --- | --- |

—

for PS Parent, LLC: transportation of freight on flatbed trailers, multi-modal freight brokerage, logistics services and warehousing services, outside of the European Economic Area.

3.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10388 – Gamut/BCI/PS Parent

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---
EXHIBIT 15.1

                      AWARENESS LETTER OF INDEPENDENT ACCOUNTANTS

Securities and Exchange Commission
450 Fifth Street, N.W.

Washington, D.C. 20549

                                                    Re: OYO Geospace Corporation
                                                       Registration on Form S-8

We are aware that our report dated April 28, 1998, on our review of interim
financial information of OYO Geospace Corporation as of and for the three months
and six months ended March 31, 1998, and included in the Company's quarterly
report on Form 10-Q for the quarter then ended is incorporated by reference in
the Company's registration statement on Form S-8 (333-40893). Pursuant to Rule
436(c) under the Securities Act of 1933, this report should not be considered a
part of the registration statement prepared or certified by us within the
meaning of Sections 7 and 11 of that Act.

                                                   /s/ COOPERS & LYBRAND L.L.P.

Houston, Texas
May 5, 1998
#### All data considered provisional and subject to revision.

      Storage                    
csv

      Pool Elevation                    
csv

      Inflow                    
csv

      Inflow Volume                    
csv

      Total Release                    
csv

      Release Volume                    
csv

      Area                    
csv

      Evaporation                    
csv

      Delta Storage                    
csv

#### All data considered provisional and subject to revision.

      Storage                    
json

      Pool Elevation                    
json

      Inflow                    
json

      Inflow Volume                    
json

      Total Release                    
json

      Release Volume                    
json

      Area                    
json

      Evaporation                    
json

      Delta Storage                    
json
Listen

# Commission Business Meeting

In accordance with the Government in Sunshine Act (5 U.S.C. 552b), the Commission on Civil Rights is holding a meeting to discuss the Commission’s business for the month of July.

Friday, July 21, 2023 - 10:00 AM

Notice and Agenda

Transcript (Unedited)

July 21, 2023

-  Event Calendar 
-  Public Briefings 
-  Commission Business Meetings 
-  Advisory Committees Meetings 
-  Archives
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<RESTATED>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                      20,994,026
<SECURITIES>                                         0
<RECEIVABLES>                               10,560,364
<ALLOWANCES>                                   118,890
<INVENTORY>                                          0
<CURRENT-ASSETS>                            33,389,348
<PP&E>                                      16,385,809
<DEPRECIATION>                               7,298,866
<TOTAL-ASSETS>                              44,837,148
<CURRENT-LIABILITIES>                        5,568,572
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       155,507
<OTHER-SE>                                  37,240,907
<TOTAL-LIABILITY-AND-EQUITY>                44,837,148
<SALES>                                     27,287,970
<TOTAL-REVENUES>                            27,287,970
<CGS>                                       12,705,193
<TOTAL-COSTS>                               11,288,586
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             279,736
<INCOME-PRETAX>                              4,067,956
<INCOME-TAX>                                   474,791
<INCOME-CONTINUING>                          3,593,165
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 3,593,165
<EPS-PRIMARY>                                     0.25
<EPS-DILUTED>                                     0.21


</TABLE>
Exhibit 99.3


                           CERTIFICATION PURSUANT TO
                                SECTION 906 OF
                        THE SARBANES-OXLEY ACT OF 2002



          In connection with the Quarterly Report of Blount International,
Inc. (the "Company") on Form 10-Q for the period ending June 30, 2003 as
filed with the Securities and Exchange Commission on the date hereof (the
"Report"), I, James S. Osterman, Chief Executive Officer of the Company,
certify, pursuant to 18 U.S.C. {section} 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that, to such officer's knowlege:

      (i)  The Report fully complies with the requirements of Section 13(a) or
      15(d) of the Securities Exchange Act of 1934; and

      (ii) The information contained in the Report fairly presents, in all
      material respects, the financial condition and results of operations of
      the Company as of the dates and for the periods expressed in the report.

A signed original of this written statement required by section 906 has been
provided to Blount International, Inc. and will be retained by Blount
International, Inc. and furnished to the Securities and Exchange Commission or
its staff upon request.


Date: November 19, 2004

/s/ James S. Osterman
--------------------------------
James S. Osterman
President and
Chief Executive Officer
JASPERS + HALL, PC CERTIFIED PUBLIC ACCOUNTANTS 9175 E Kenyon Avenue Denver, CO 80237 303-796-0099  Board of Directors GeneThera, Inc. Wheat Ridge, CO  REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM  We have audited the accompanying consolidated balance sheets of GeneThera, Inc. and subsidiary as of December 31, 2007 and 2006, and the related statements of operations, stockholders deficit and cash flows for the years then ended and for the period from January 1, 2005 to December 31, 2007.  These financial statements are the responsibility of the Companys management.  Our responsibility is to express an opinion on these financial statements based on our audits. The cumulative financial statements for the period October 5, 1998 (inception) to December 31, 2004, were audited by other accountants, whose report dated February 28, 2005, expressed an unqualified opinion on those statements however they did express concern regarding the Companys ability to continue as a going concern. They have not performed any auditing procedures since that date.  We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the companys internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.  An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audits provide a reasonable basis for our opinion.  In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of GeneThera, Inc. and subsidiary. as of December 31, 2007 and 2006, and the results of their operations and their cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.  The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  As discussed in Note 9 to the financial statements, the Companys accumulated deficit from operations and its difficulties in maintaining sufficient working capital raise substantial doubt about its ability to continue as a going concern.  Managements plans concerning these matters are also described in Note 9.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.   Jaspers + Hall, PC Denver, Colorado October 14, 2008
[Federal Register Volume 86, Number 176 (Wednesday, September 15, 2021)]
[Notices]
[Page 51362]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-19936]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases; 
Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; RFA DK21-005 Immune Cell 
Engineering for Type 1 Diabetes.
    Date: November 15-16, 2021.
    Time: 10:00 a.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Two Democracy Plaza, 6707 
Democracy Boulevard, Bethesda, MD 20892 (Video Meeting).
    Contact Person: Ann A. Jerkins, Ph.D., Scientific Review 
Officer, Review Branch, DEA, NIDDK, National Institutes of Health, 
Room 7119, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, 301-
594-2242, <a href="/cdn-cgi/l/email-protection#214b44534a484f5240614f4845454a0f4f48490f464e57"><span class="__cf_email__" data-cfemail="4d27283f2624233e2c0d232429292663232425632a223b">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology 
and Hematology Research, National Institutes of Health, HHS)

    Dated: September 10, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-19936 Filed 9-14-21; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Skip to main content

Privacy Policy•Site map

# Help

If you are unable to find an answer to your question on our website, please call our CM/ECF Help Desk during regular court business hours (Monday through Friday, 8:30 am - 4:30 pm EST) at 1-866-784-6273 (toll free) or 202-357-6402 (local). Please note that the Clerk’s Office cannot access or update individual ECF account information, including login credentials. Thus, account maintenance questions should be directed to the PACER Service Center at www.pacer.gov or (800) 676-6856.

Howard T. Markey National Courts Building • 717 Madison Place, NW, Washington, DC 20439 • 202-357-6400
<PAGE>   1
                                  EXHIBIT 10.2

                          AMENDMENT TO PROMISSORY NOTE
                          ----------------------------

     THIS AMENDMENT dated at of October 29, 1999, (the "Amendment") is made by
and between Dr. Douglas Reed (the "Borrower") and GelTex Pharmaceuticals, Inc.,
a Delaware corporation (the "Lender") and amends the Promissory Note in the
amount of $150,000 executed in Waltham, Massachusetts and dated December 31,
1998.

                                 R E C I T A L S

     WHEREAS, Dr. Douglas Reed and GelTex Pharmaceuticals, Inc. are parties to
that certain Promissory Note dated December 31, 1998;

     WHEREAS, Dr. Douglas Reed and GelTex Pharmaceuticals, Inc. desire to amend
the Promissory Note to extend the Maturity Date of said note;

     NOW, THEREFORE, the parties mutually agree as follows:

     The Maturity Date of this Promissory Note shall be the earlier of (i)
fifteen days following the closing date of the Borrower's sale of the property
located at 3021 E. Thackeray Place, Salt Lake City, Utah or (ii) March 31, 2000.

     Executed as a sealed instrument as of the day and year first above written.

BORROWER:

 /s/ Douglas Reed
-------------------------------
Douglas Reed

LENDER:

GELTEX PHARMACEUTICALS, INC.

By:

/s/ Paul J. Mellett, Jr.
-------------------------------
Paul J. Mellett, Jr., Vice President
Finance and Administration
Exhibit 32.2



PERICOM SEMICONDUCTOR CORPORATION



CERTIFICATION OF CHIEF FINANCIAL OFFICER



PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED



PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with this quarterly report of Pericom Semiconductor Corporation (the Company) on Form 10-Q for the three months ended March 26, 2005 (the
Report), I, Michael D. Craighead, Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:



(1) the Report fully complies with the requirements of
Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and



(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.



May 4, 2005



By:

/s/ Michael D. CraigheadMichael D. CraigheadChief Financial OfficerPericom Semiconductor Corporation
Listen

# Reverend Al Sharpton

## CSSBMB Commissioner

Commissioner Sharpton is an internationally renowned civil rights leader and founder and President of the National Action Network (NAN). For decades, he has dedicated his life to the fight for justice and equality, turning the power of dissent and protest into tangible legislation impacting the lives of the disenfranchised. As head of NAN, Rev. Sharpton has taken the teachings of the Rev. Dr. Martin Luther King, Jr. and applied them to a modern civil rights agenda. He has been a tireless advocate for everything from police reform and accountability to protection of voting rights and education equality. Reverend Sharpton has been at the forefront of the modern civil rights movement for nearly a half century. He has championed police reform and accountability, calling for the elimination of unjust policies like "Stop-and-Frisk."

*Photo courtesy of Christopher Moore at www.christophermooremedia.com*

-  Our Mission 
-  Commissioners 
-  Offices and Staff 
-  Careers 
-  Acquisition Opportunities 
-  Rankin Memorial Library 
-  FAQs
<PAGE>

                                                                    EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of TransAct Technologies Incorporated (the
"Company") on Form 10-K for the period ending December 31, 2006, as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I,
Bart C. Shuldman, Chief Executive Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that to the best of my knowledge:

     (1)  The Report fully complies with the requirements of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and results of operations
          of the Company.

Date:  March 15, 2007


/s/ Bart C. Shuldman
------------------------------------
Bart C. Shuldman
Chief Executive Officer


                                       63
**EXHIBIT
      14.1**




**Consent
      of Independent Registered Public Accounting Firm**




The
      Board
      of Directors


RADCOM
      Ltd.


Tel
      Aviv


Israel




We
      consent to the incorporation by reference in the Registration Statement (File
      No. 333-07964, No. 333-13244, No. 333-13246, No. 333-13248, No. 333-13250,
      No.
      333-13252, No. 333-13254, No. 333-14236, No. 333-111931 and No.333-123981)
      on
      Form S-8 and in the Registration Statement on Form F-3 (File No. 333-115475)
      of
      RADCOM Ltd. of our report dated June 30, 2008, with respect to the consolidated
      balance sheets of RADCOM Ltd. as of December 31, 2007 and 2006 and the related
      consolidated statements of operations, shareholders’ equity and comprehensive
      income (loss) and cash flows for each of the years in the three-year period
      ended December 31, 2007, which report appears in the December 31, 2007 Annual
      Report on Form 20-F of RADCOM Ltd.




Our
      report on the consolidated financial statements refers to the adoption by RADCOM
      Ltd. of Statement of Financial Accounting Standard No. 123R “Share-Based
      Payment,” effective January 1, 2006.





*/s/Somekh
                Chaikin*Somekh
                ChaikinCertified
                Public Accountants (Isr.)Member
                Firm of KPMG International
              
              Tel-Aviv,
                Israel
              June
                30, 2008
IN THE DISTRICT COURT OF APPEAL OF THE STATE OF FLORIDA FIFTH DISTRICT

NOT FINAL UNTIL TIME EXPIRES TO FILE MOTION FOR REHEARING AND DISPOSITION THEREOF IF FILED
LEVERT STEWART ,

Appellant ,

v. Case No. 5D2 3 -1027 LT Case No. 2008-C F -007205-A
STATE OF FLORIDA ,

Appellee

. ________________________________/
Decision filed May 9, 2023 3.800 Appeal from the Circuit Court for Duval County , Tatiana Salvador , Judge. Levert Stewart, Raiford, pro se. No Appearance for Appellee.

PER CURIAM.

AFFIRMED.

LAMBERT , C.J., HARRIS and KILBANE, JJ., concur.
[865 NE2d 1223, 834 NYS2d 57]

#### Margo Lennard, Appellant, v Mendik Realty Corp. et al., Respondents and Third-Party Plaintiffs. City of New York, Third-Party Defendant-Respondent.

Decided March 29, 2007

*910APPEARANCES OF COUNSEL

*Sullivan Papain Block McGrath & Cannavo P.C.,*New York City *(Brian J. Shoot*of counsel), for appellant.

*Law Offices of Charles J. Siegel,*New York City *(Jack L. Cohen*of counsel), for respondents and third-party plaintiffs.

*Michael A. Cardozo, Corporation Counsel,*New York City *(Kristin M. Helmers*of counsel), for third-party defendant-respondent.

OPINION OF THE COURT

Memorandum.

The order of the Appellate Division should be reversed, with costs, and the case remitted to that Court for consideration of issues raised but not determined on the appeal to that Court.

Plaintiff contends that she was injured when she slipped and fell on loose floor tiles in a bathroom at her workplace. Defendants, owners and managers of the premises, failed to establish that they lacked constructive notice of the allegedly defective floor tiles as a matter of law *(see Gordon v American Museum of Natural History,*67 NY2d 836, 837 [1986]; *see also Chapman v Silber,*97 NY2d 9, 19 [2001]). Accordingly, summary judgment was not appropriate.

Chief Judge Kaye and Judges Ciparick, Graffeo, Read, Smith, Pigott and Jones concur in memorandum.

On review of submissions pursuant to section 500.11 of the Rules of the Court of Appeals (22 NYCRR 500.11), order reversed, etc.